Teva Pharmaceutical Industries (TEVA) Set to Announce Quarterly Earnings on Wednesday

Teva Pharmaceutical Industries (NYSE:TEVA) will issue its quarterly earnings data before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.49 per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $13.98 on Monday. Teva Pharmaceutical Industries has a 12 month low of $7.09 and a 12 month high of $14.47. The stock has a market cap of $15.67 billion, a PE ratio of -29.74, a price-to-earnings-growth ratio of 1.67 and a beta of 1.04. The company’s fifty day moving average price is $13.61 and its 200-day moving average price is $11.61. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23.

Insider Activity

In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the completion of the sale, the vice president now directly owns 1 shares in the company, valued at approximately $13.05. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Richard D. Francis sold 74,530 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $13.15, for a total value of $980,069.50. Following the transaction, the chief executive officer now owns 87,125 shares in the company, valued at approximately $1,145,693.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Eric Drape sold 173,261 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the sale, the vice president now owns 1 shares of the company’s stock, valued at $13.05. The disclosure for this sale can be found here. Insiders sold 358,972 shares of company stock valued at $4,739,820 over the last three months. Insiders own 0.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TEVA. The Goldman Sachs Group raised their target price on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a research note on Monday, February 5th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price target for the company in a research report on Friday, March 8th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $12.00 to $19.00 in a research note on Monday, February 12th. Finally, Barclays upped their target price on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.